Journal for ImmunoTherapy of Cancer – Page 15

MIAT promotes tumor-infiltrating CD8+ T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway

31 de July de 2025 by

Background
The hyporesponsiveness of tumor-infiltrating exhausted CD8+ T cells to tumor cells contributes to immune escape of renal cell carcinoma (RCC), representing a major challenge in current immunotherapy. However, the underlying molecular mechan…

Mitochondrial Pathway Signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma

31 de July de 2025 by Zhang, P., Zhang, M., Liu, J., Zhou, Z., Zhang, L., Luo, P., Zhang, Z.

Background
Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer. Although immune checkpoint inhibitors (ICIs) have brought new treatment options for advanced patients, a considerable proportion still shows limited respon…

Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade

30 de July de 2025 by Ciccone, D. N., Kuo, F.-S., Boiko, S., Carreiro, S., Kaila, N., McElwee, J. J., Tummino, P. J., Loh, C.

Background
HPK1 (hematopoietic progenitor kinase 1, MAP4K1), an MAP4K serine/threonine kinase family member, is a negative regulator of immune cell function. Genetic HPK1 kinase inactivation or knockout in mice leads to immune cell activation and tumo…

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing

29 de July de 2025 by

Background
Autologous CD19 chimeric antigen receptor (CAR) T-cell therapy leads to durable responses and improved survival in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Among approved CAR T-cell products, axicabtagene cilol…

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

25 de July de 2025 by

Background
There is an unmet need for novel immunotherapies to overcome immune evasion in patients with advanced skin cancers resistant to programmed death (PD)-1 / PD-ligand 1 (PD-L1) blockade. Cavrotolimod is a novel spherical nucleic acid configura…

hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor

25 de July de 2025 by

Background
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematological malignancies; however, it faces significant challenges in treating solid tumors, including limited immune infiltration into tumor tissues and i…

Letter to the editor: LSD1 as an upstream epigenetic regulator of NPM1-PD-L1 axis in hypoxia-driven immune evasion in breast cancer

25 de July de 2025 by Iqbal, J.

Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control

24 de July de 2025 by Dysthe, M., Navin, I., van Leeuwen, D., Pineda, J., Baumgartner, C., Rooney, C. M., Parihar, R.

Background
Adoptive transfer of chimeric antigen receptor (CAR)-expressing natural killer (NK) cells has demonstrated success against hematological malignancies. Efficacy against solid tumors has been limited by poor NK cell survival and function in t…

Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy

24 de July de 2025 by Zhu, Z., Chen, H., Feng, C., Chen, L., Ma, C., Liu, Z., Qu, Z., Bartlett, D. L., Lu, B., Li, K., Guo, Z. S.

Background
Oncolytic virus (OV)-mediated immunotherapy has been shown limited efficacy. Small molecule inhibitors specific to the KRASG12C driver oncoprotein have recently been developed for cancer treatment. The combination of a potent OV with a KRAS…

Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer

24 de July de 2025 by

Background
Patients with head and neck squamous cell carcinoma (HNSCC), particularly the human papillomavirus negative (HPV–) subset, have a dismal prognosis. Furthermore, patients with Fanconi anemia (FA) have a genetic predisposition with a 50…